Sandoz Reports Strong Sales Growth in Full Year 2024
Basel, Switzerland – Sandoz, a leading global company in the field of generic and biosimilar medicines, announced its results for the full year and the fourth quarter of 2024. The company reported net sales of USD 10.4 billion for the year, marking a 9% increase in constant currencies and a 7% rise in USD.
Strong Sales Performances Across Regions
Sandoz achieved double-digit growth in biosimilars during the fourth quarter and the full year, with sales reaching USD 2.7 billion in the final quarter and USD 7.3 billion for the entire year. This growth was driven by recent launches and base-business momentum in all three regions: Europe, North America, and the Rest of the World.
Operating Income and Core EBITDA Margin
Operating income for the year was USD 307 million, which represents a 5% increase in constant currencies but a 18% decrease in USD. The company’s core EBITDA margin stood at 20.1% for the year, reflecting a strong 200 basis-point improvement.
Full-Year 2025 Guidance
Looking ahead, Sandoz expects mid-single digit net sales growth and a core EBITDA margin of around 21% for the full year of 2025.
Impact on Consumers: Lower Costs for Essential Medicines
Sandoz’s strong sales growth in biosimilars is likely to lead to lower costs for essential medicines, as biosimilars are generally priced lower than their branded counterparts. This could result in more affordable healthcare options for consumers around the world.
Impact on the World: Expansion of Access to Affordable Medicines
The continued growth of Sandoz in the biosimilars market is expected to contribute to the expansion of access to affordable medicines in both developed and developing countries. This could lead to improved health outcomes and reduced healthcare costs for governments and individuals.
Conclusion
Sandoz’s strong sales performance in 2024, driven by double-digit growth in biosimilars, is a positive sign for the global healthcare industry. The company’s continued focus on operational and organizational initiatives, as well as its commitment to launching new products, positions Sandoz well for future success. The anticipated lower costs for essential medicines and increased access to affordable healthcare options could have significant implications for consumers and governments around the world.
- Sandoz reports net sales of USD 10.4 billion in 2024, up by 9% in constant currencies
- Biosimilars drive sales growth, with double-digit increases in both Q4 and full-year sales
- Operating income of USD 307 million, with a core EBITDA margin of 20.1%
- Mid-single digit net sales growth and a core EBITDA margin of around 21% expected for 2025
- Strong sales growth in biosimilars to lead to lower costs for essential medicines
- Expansion of access to affordable medicines in developed and developing countries
